PL1636261T3 - Białka trombopoetynowe o ulepszonych właściwościach - Google Patents

Białka trombopoetynowe o ulepszonych właściwościach

Info

Publication number
PL1636261T3
PL1636261T3 PL04740298T PL04740298T PL1636261T3 PL 1636261 T3 PL1636261 T3 PL 1636261T3 PL 04740298 T PL04740298 T PL 04740298T PL 04740298 T PL04740298 T PL 04740298T PL 1636261 T3 PL1636261 T3 PL 1636261T3
Authority
PL
Poland
Prior art keywords
tpo
improved
thrombopoietin
proteins
improved properties
Prior art date
Application number
PL04740298T
Other languages
English (en)
Inventor
Matthew Baker
John Watkins
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL1636261T3 publication Critical patent/PL1636261T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL04740298T 2003-06-26 2004-06-25 Białka trombopoetynowe o ulepszonych właściwościach PL1636261T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03014331 2003-06-26
PCT/EP2004/006887 WO2005000891A2 (en) 2003-06-26 2004-06-25 Thrombopoietin proteins with improved properties
EP04740298A EP1636261B1 (en) 2003-06-26 2004-06-25 Thrombopoietin proteins with improved properties

Publications (1)

Publication Number Publication Date
PL1636261T3 true PL1636261T3 (pl) 2007-12-31

Family

ID=33547598

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04740298T PL1636261T3 (pl) 2003-06-26 2004-06-25 Białka trombopoetynowe o ulepszonych właściwościach

Country Status (9)

Country Link
US (1) US7541439B2 (pl)
EP (1) EP1636261B1 (pl)
AT (1) ATE368687T1 (pl)
DE (1) DE602004007924T2 (pl)
DK (1) DK1636261T3 (pl)
ES (1) ES2289528T3 (pl)
PL (1) PL1636261T3 (pl)
PT (1) PT1636261E (pl)
WO (1) WO2005000891A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098547A1 (en) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
AU2008279550B2 (en) * 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
NZ583362A (en) 2007-08-15 2012-06-29 Circassia Ltd Peptide with reduced dimer formation
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
EP2390261A4 (en) * 2009-01-20 2012-11-14 Hanall Biopharma Co Ltd MODIFIED HUMAN THROMBOPOIETIN POLYPEPTIDE FRAGMENT AND METHOD FOR THE PRODUCTION THEREOF
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP2943512A4 (en) 2013-01-11 2016-06-01 California Inst Biomedical Res BOVINE FUSION ANTIBODY
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
CN106661128A (zh) * 2014-06-06 2017-05-10 加州生物医学研究所 构建氨基末端免疫球蛋白融合蛋白的方法及其组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6238890B1 (en) * 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
BR0207542A (pt) * 2001-02-26 2004-03-09 Merck Patent Gmbh Trombopoietina modificada com imunogenicidade reduzida
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
DK1578772T3 (da) * 2002-05-01 2010-08-16 Danisco Us Inc Cytokiner og cytokinreceptorer med reduceret immunogenicitet

Also Published As

Publication number Publication date
DE602004007924T2 (de) 2008-04-10
ES2289528T3 (es) 2008-02-01
WO2005000891A3 (en) 2005-04-21
EP1636261B1 (en) 2007-08-01
US20060160995A1 (en) 2006-07-20
WO2005000891A2 (en) 2005-01-06
EP1636261A2 (en) 2006-03-22
DE602004007924D1 (de) 2007-09-13
DK1636261T3 (da) 2007-11-12
ATE368687T1 (de) 2007-08-15
PT1636261E (pt) 2007-11-08
US7541439B2 (en) 2009-06-02

Similar Documents

Publication Publication Date Title
DE602004011770D1 (de) Fusionsproteine
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
EA200600869A1 (ru) Антитела, связывающие рецептор интерлейкина-4
DE60032486D1 (de) Prion protein peptide und deren verwendung
WO2007091250A3 (en) Enzyme replacement therapy for treating lysosomal storage diseases
WO2006121610A3 (en) Personal care compositions and methods for their use
PL1636261T3 (pl) Białka trombopoetynowe o ulepszonych właściwościach
DK2229440T3 (da) Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf
ATE527237T1 (de) Modifizierter mscl-proteinkanal
EP1544214A4 (en) Non-neutralizing anti-aPC antibodies
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin
TW200724679A (en) Treatment of disease using an improved regulated expression system
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system
WO2007134907A3 (en) Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
WO2005035564A3 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
EA200700346A1 (ru) Бактериофаг- и профаг-специфические протеины в генной терапии рака
WO2006110367A3 (en) Methods and compositions for mycoplasma toxins
ATE405249T1 (de) Körpergeruch verändernde biologisch aktive substanzen
WO2006000464A3 (de) Verfahren zum auffinden schmerzrelevanter substanzen unter verwendung schmerzrelevanter proteine